Unnamed Speaker 1

Yeah, yeah. Brain tissue. Okay. Wow, that's wild. Yeah, it's pretty interesting. One of the interesting elements of DMT is it's neuroprotective in ischemia. What does that mean? Well, it means when you expose a neuron to low oxygen levels, it will die. Okay. And with DMT, it allows the neuron to live longer. Oh, interesting. Yeah, and it also reduces stroke size.

Yeah, yeah. Brain tissue. Okay. Wow, that's wild. Yeah, it's pretty interesting. One of the interesting elements of DMT is it's neuroprotective in ischemia. What does that mean? Well, it means when you expose a neuron to low oxygen levels, it will die. Okay. And with DMT, it allows the neuron to live longer. Oh, interesting. Yeah, and it also reduces stroke size.

Yeah, yeah. Brain tissue. Okay. Wow, that's wild. Yeah, it's pretty interesting. One of the interesting elements of DMT is it's neuroprotective in ischemia. What does that mean? Well, it means when you expose a neuron to low oxygen levels, it will die. Okay. And with DMT, it allows the neuron to live longer. Oh, interesting. Yeah, and it also reduces stroke size.

There's a Hungarian group that's been working on that. So it's starting to be studied anyway in stroke because it's neuroprotective, and it is like a classical psychedelic. It stimulates neurogenesis.

There's a Hungarian group that's been working on that. So it's starting to be studied anyway in stroke because it's neuroprotective, and it is like a classical psychedelic. It stimulates neurogenesis.

There's a Hungarian group that's been working on that. So it's starting to be studied anyway in stroke because it's neuroprotective, and it is like a classical psychedelic. It stimulates neurogenesis.

Yeah, yeah. There's a group in Canada, Algernon, that I've been consulting with or I have been consulting with that is working on a DMT stroke study.

Yeah, yeah. There's a group in Canada, Algernon, that I've been consulting with or I have been consulting with that is working on a DMT stroke study.

Yeah, yeah. There's a group in Canada, Algernon, that I've been consulting with or I have been consulting with that is working on a DMT stroke study.

Yeah, they've worked out the model. It's six or eight hours of sub-psychedelic dose of DMT. It still will have some biological effects, but it's not especially mind-altering. So it's a low, steady dose.

Yeah, they've worked out the model. It's six or eight hours of sub-psychedelic dose of DMT. It still will have some biological effects, but it's not especially mind-altering. So it's a low, steady dose.

Yeah, they've worked out the model. It's six or eight hours of sub-psychedelic dose of DMT. It still will have some biological effects, but it's not especially mind-altering. So it's a low, steady dose.

Yeah.

Yeah.

Yeah.

Oh, yeah. Yeah, they're moving ahead with, I think, clinical work, although I'm just not sure. But I think they're thinking about clinical work at least.

Oh, yeah. Yeah, they're moving ahead with, I think, clinical work, although I'm just not sure. But I think they're thinking about clinical work at least.

Oh, yeah. Yeah, they're moving ahead with, I think, clinical work, although I'm just not sure. But I think they're thinking about clinical work at least.

Yeah.

Yeah.